PRESS: British Pain Society features Celadon Pharmaceuticals Plc
For those leading the company, this has been a very personal mission to produce a high-quality trial for cannabis-based medicines. James Short (CEO and co-founder of Celadon Pharmaceuticals Plc) saw his sister’s experience of living with multiple sclerosis for years and also witnessed first-hand the potential benefits of cannabis-based medicines for her condition. James also spent months talking to patients across the United Kingdom – as well as travelling to Canada – who were already using such medicines for a variety of conditions and decided to found Celadon in 2018, with a focus on evidence-based medicines for chronic pain. Despite witnessing these accounts of how cannabis-based medicinal products (CBMPs) could transform the lives of those suffering pain, James was acutely aware of the lack of published high-quality evidence in the United Kingdom to support doctors in prescribing CBMPs. Read the full story in the British Pain Society above.
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces Interim Results
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework